acetaminophen has been researched along with Tetanus in 3 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Tetanus: A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since fever is an important issue with vaccine tolerability, we performed this open-label study on the efficacy and safety of prophylactic use of paracetamol (acetaminophen, Benuron®) in children administered routine 7-valent pneumococcal conjugate vaccine (PCV-7) coadministered with hexavalent vaccine (diphtheria-tetanus-acellular pertussis-hepatitis B, poliovirus, Haemophilus influenzae type b vaccine [DTPa-HBV-IPV/Hib]) in Germany." | 5.17 | An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Hae ( Baker, S; Gruber, WC; Juergens, C; Rose, MA; Schmoele-Thoma, B; Zielen, S, 2013) |
| "Low grade fever is a known adverse effect of vaccination." | 2.84 | Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants. ( Bavdekar, SB; Chhatwal, J; D'Cor, NA; Dhaded, SM; Dhingra, MS; Dubey, AP; Dupuy, M; Gandhi, DJ; Gupta, M; Jayanth, MV; Kundu, R; Lalwani, SK; Mangarule, SA; Mathew, LG; Patnaik, BN; Ravi, MD; Ravinuthala, S; Reddy E, J; Rout, SP; Sharma, SD; Sil, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sil, A | 1 |
| Ravi, MD | 1 |
| Patnaik, BN | 1 |
| Dhingra, MS | 1 |
| Dupuy, M | 1 |
| Gandhi, DJ | 1 |
| Dhaded, SM | 1 |
| Dubey, AP | 1 |
| Kundu, R | 1 |
| Lalwani, SK | 1 |
| Chhatwal, J | 1 |
| Mathew, LG | 1 |
| Gupta, M | 1 |
| Sharma, SD | 1 |
| Bavdekar, SB | 1 |
| Rout, SP | 1 |
| Jayanth, MV | 1 |
| D'Cor, NA | 1 |
| Mangarule, SA | 1 |
| Ravinuthala, S | 1 |
| Reddy E, J | 1 |
| Rose, MA | 1 |
| Juergens, C | 1 |
| Schmoele-Thoma, B | 1 |
| Gruber, WC | 1 |
| Baker, S | 1 |
| Zielen, S | 1 |
| Oldfield, BJ | 1 |
| Stewart, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation: the NEED LESS PAIN Study"[NCT02807623] | 300 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administration of a 7-Valent Pneumococcal Conjugate Vaccine (Pre[NCT00294294] | Phase 4 | 300 participants | Interventional | 2005-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Swelling at vaccination site (NCT02807623)
Timeframe: baseline, 48-72 hours, and 21- 28 days (3 points)
| Intervention | Participants (Count of Participants) |
|---|---|
| Baseline | 0 |
| 48-72 Hours After Vaccination | 0 |
| 21-28 Days After Vaccination | 0 |
Reddening of the skin at vaccination site reported as the total number of participants with erythema over the duration of the study. (NCT02807623)
Timeframe: baseline, 48- 72 hours, 21-28 days (3 points)
| Intervention | Participants (Count of Participants) |
|---|---|
| Baseline | 0 |
| 48-72 Hours After Vaccination | 0 |
| 21-28 Days After Vaccination | 0 |
A Lactate meter was used to test the exercise group for lactate readings. Two lactate tests was performed for the exercise group at Visit 1, both pre and post Influenza vaccination. The first lactate reading was taken after the blood draw.The second lactate reading was obtained from a fingerstick from the hand opposite to the vaccination arm, ideally within 3-8 minutes after the study subject completes pushups. (NCT02807623)
Timeframe: Immediately prior to Influenza vaccine and 3-8 minutes after Influenza vaccine was administered and after push-ups were completed.
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Lactate before pushups | Lactate after pushups | |
| Compound Exercise of Push-ups | 1.51 | 7.69 |
Level of Pain will be measured by validated pain scale, using a scale of 0 ( best, no pain) to 10 (worst, as bad as imaginable, completely interferes). (NCT02807623)
Timeframe: baseline, 48-72 hours and at 21-28 days ( 3 points )
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | |
| Compound Exercise of Push-ups | .14 | .19 | .13 |
| Ibuprofen | .39 | .56 | .28 |
| Placebo | .19 | .22 | .06 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 214.80 | 345.09 |
| Ibuprofen | 171.00 | 239.25 |
| Placebo | 216.75 | 343.03 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 149.22 | 232.58 |
| Ibuprofen | 177.78 | 243.13 |
| Placebo | 221.09 | 296.66 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 26.00 | 41.02 |
| Ibuprofen | 17.41 | 25.47 |
| Placebo | 26.09 | 34.09 |
Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)
| Intervention | Titer (Mean) | |
|---|---|---|
| Baseline (day 0, visit 1) | Followup (between 21-28 days, visit 3) | |
| Compound Exercise of Push-ups | 32.89 | 49.07 |
| Ibuprofen | 40.16 | 47.34 |
| Placebo | 36.69 | 44.78 |
1 review available for acetaminophen and Tetanus
| Article | Year |
|---|---|
Common Misconceptions, Advancements, and Updates in Pediatric Vaccination Administration.
Topics: Acetaminophen; Adolescent; Bacterial Infections; Child; Child, Preschool; Family; Female; Guidelines | 2016 |
2 trials available for acetaminophen and Tetanus